Pancreatic cancer is an aggressive tumor with a dismal prognosis, biomarkers that can
detect tumor in its early stages when it may be amenable to curative resection may improve …

Several advances in genetics, diagnosis and palliation of pancreatic cancer (PC) have
occurred in the last decades. A multidisciplinary approach to this disease is therefore …

Background Serum carbohydrate antigen (CA 19-9) is the most common tumor marker
assessed in pancreatic cancer patients; nevertheless few articles have comprehensively …

Background. Current methods to predict survival duration of patients with pancreatic cancer
are limited. The aim of this study was to determine whether certain nutritional indices and the …

Chemotherapy with gemcitabine has been shown to be an effective regimen in advanced or
metastatic pancreatic cancer with improvement of both quality of life and survival time. The …

Unresectable pancreatic cancer has a dismal prognosis with a median survival of 3–5
months in untreated disease. Since the introduction of gemcitabine, pancreatic cancer may …

Background Pancreatic cancer is one of the most deadly cancers, and serum carbohydrate
antigen 19-9 (CA19-9) level has been reported to be a useful prognostic marker in …

In pancreatic cancer (PC) accurate determination of treatment response by imaging often
remains difficult. Various efforts have been undertaken to investigate new factors which may …

The concentration of the tumor marker CA 19-9 is influenced by the patient's secretor status
and Lewis genotype. The aim of this study was to establish novel reference intervals for CA …

Abstract Serum carbohydrate antigen 19-9 (CA 19-9) has been identified as a useful tumour
marker for diagnosis of exocrine pancreatic carcinoma, but its value for evaluating the …